Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study
dc.creator | Anagnostou, O. | en |
dc.creator | Manolakopoulos, S. | en |
dc.creator | Bakoyannis, G. | en |
dc.creator | Papatheodoridis, G. | en |
dc.creator | Zisouli, A. | en |
dc.creator | Raptopoulou-Gigi, M. | en |
dc.creator | Manesis, E. | en |
dc.creator | Ketikoglou, I. | en |
dc.creator | Dalekos, G. | en |
dc.creator | Gogos, C. | en |
dc.creator | Vassiliadis, T. | en |
dc.creator | Tzourmakliotis, D. | en |
dc.creator | Karatapanis, S. | en |
dc.creator | Kanatakis, S. | en |
dc.creator | Zoumpoulis-Vafiadis, I. | en |
dc.creator | Hounta, A. | en |
dc.creator | Koutsounas, S. | en |
dc.creator | Giannoulis, G. | en |
dc.creator | Tassopoulos, N. | en |
dc.creator | Touloumi, G. | en |
dc.date.accessioned | 2015-11-23T10:22:10Z | |
dc.date.available | 2015-11-23T10:22:10Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 1108-4189 | |
dc.identifier.uri | http://hdl.handle.net/11615/25530 | |
dc.description.abstract | Background and aim: Patients with genotype 4 (G4) chronic hepatitis C (CHC) are considered a difficult to treat population, although current data on G4 treatment responsiveness and duration are controversial. Greece represents a country with an intermediate prevalence of G4 infections, offering an opportunity to compare treatment outcomes by genotype and to identify potential prognostic factors for sustained virologic response (SVR). Methods: All CHC patients from the HepNet. Greece, an ongoing nationwide cohort study on viral hepatitis, with known hepatitis C virus (HCV) genotype who received treatment with Peg-IFNa and ribavirin were analyzed. Results: From 4443 patients, 951 (61.7% males, 78.4% Greeks, median age 40.6 years, 10% cirrhosis) fulfilled the inclusion criteria. G4 was found in 125 (13.1%) patients. Genotype distribution was not significantly different between Greeks and immigrants. Patients with G4 had similar odds of SVR compared to G1 but significantly lower compared to G2/G3. Age, treatment discontinuation, presence of cirrhosis and previous history of HCV-treatment were associated with lower probabilities of SVR. Ethnicity did not affect SVR for all genotypes while response to treatment was similar between Greek and Egyptian patients groups (35.7% vs 40.9%, p= 0.660%) with G4 infection. The relation between SVR and genotype did not substantially change after adjustment for age, gender, cirrhosis, treatment interruption and history of HCV-treatment. Conclusions: The findings of this large cohort of CHC patients with a well balanced genotype distribution further supports the idea of considering G4 as a difficult to treat genotype. Further investigation is needed to identify genotype specific prognostic factors. | en |
dc.source | Hippokratia | en |
dc.source.uri | <Go to ISI>://WOS:000335442400012 | |
dc.subject | Viral hepatitis | en |
dc.subject | HCV treatment | en |
dc.subject | interferon | en |
dc.subject | pegylated-interferon | en |
dc.subject | CHRONIC HEPATITIS-C | en |
dc.subject | ALPHA-2B PLUS RIBAVIRIN | en |
dc.subject | SUSTAINED VIROLOGICAL | en |
dc.subject | RESPONSE | en |
dc.subject | PEGINTERFERON ALPHA-2B | en |
dc.subject | VIRUS-INFECTION | en |
dc.subject | MOLECULAR | en |
dc.subject | EPIDEMIOLOGY | en |
dc.subject | TREATMENT DURATION | en |
dc.subject | LIVER FIBROSIS | en |
dc.subject | CIRRHOSIS | en |
dc.subject | POLYMORPHISM | en |
dc.subject | Medicine, General & Internal | en |
dc.title | Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |